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Abstract
Cellular and plasma lipid levels are tightly controlled by complex gene regulatory mechanisms.
Elevated plasma lipid content, or hyperlipidemia, is a significant risk factor for cardiovascular
morbidity and mortality. MicroRNAs (miRNAs) are posttranscriptional regulators of gene
expression and have emerged as important modulators of lipid homeostasis, but the extent of their
role has not been systematically investigated. In this study, we performed high-throughput small
RNA sequencing and detected approximately 150 miRNAs in mouse liver. We then employed an
unbiased, in silico strategy to identify miRNA regulatory hubs in lipid metabolism, and miR-27b
was identified as the strongest such hub in human and mouse liver. In addition, hepatic miR-27b
levels were determined to be sensitive to plasma hyperlipidemia, as evidenced by its ~3-fold up-
regulation in the liver of mice on a high-fat diet (42% calories from fat). Further, we showed in a
human hepatocyte cell line (Huh7) that miR-27b regulates the expression (mRNA and protein) of
several key lipid-metabolism genes, including Angptl3 and Gpam. Finally, we demonstrated that
hepatic miR-27b and its target genes are inversely altered in a mouse model of dyslipidemia and
atherosclerosis.
Conclusion—miR-27b is responsive to lipid levels, and controls multiple genes critical to
dyslipidemia.
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Cellular and plasma lipid levels are tightly controlled by complex feed-back and feed-
forward mechanisms, which regulate the expression and activity of key metabolic genes(1)
at both the transcriptional and post-transcriptional levels(2, 3). Dysregulation of lipid
metabolism can lead to hyperlipidemia, a major risk factor for cardiovascular disease(4).
Several key process for regulating cellular and systemic lipid levels have been identified(5);
however, post-transcriptional mechanisms remain less well characterized.
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MicroRNAs (miRNAs) are short (~22 nt) non-coding RNAs that regulate gene expression at
the post-transcriptional level(6, 7). They serve as stable plasma biomarkers for various
disorders(8), are important factors in the pathogenesis of several diseases(9, 10), and are
promising targets of novel therapeutic strategies(11, 12). In regard to lipid metabolic control,
miRNAs have recently been found to modulate cholesterol homeostasis(13). In vivo
inhibition of a liver-specific miRNA, miR-122, significantly lowers plasma cholesterol
levels in both mice and non-human primates(14–16). In addition, miR-33, which is encoded
within an intron of SREBF2, is co-transcribed with SREBF2 and regulates the expression of
the ATP-binding cassette transfer protein (ABCA1), a critical player in reverse cholesterol
transport and in lipoprotein biogenesis(17–19). miR-33 has also been shown to regulate fatty
acid oxidation in hepatic cell lines(20). Nevertheless, despite these important advances, the
full extent of post-transcriptional control of lipid metabolism by miRNAs remains
incompletely understood and has not been systematically investigated(21).
Using a novel in silico approach, which should be generally applicable toward the
identification of key regulatory miRNAs in any biological process, we predicted miR-27b as
a regulatory hub in lipid metabolism. Furthermore, we demonstrate that hepatic miR-27b is
responsive to lipid levels and regulates the expression (mRNA and protein) of key metabolic
genes, including angiopoietin-like 3 (ANGPTL3) and glycerol-3-phosphate acyltransferase 1




Eight-week old wild-type C57BL/6J mice were placed on either normal chow diet (4% fat,
NIH-31 open chow, Zeigler Brothers, Gardners, PA) or high-fat Western diet (21% fat, 42%
calories from fat, ad libitum, TD88137, Harlan-Teklad, Frederick, MD) for three weeks (19–
21 days). Adult (8–10 wk) female apolipoprotein E null mice (Apoe−/−, C57BL/6J
background, The Jackson Laboratory, Bar Harbor, ME) were placed on either normal chow
or Cocoa butter diet with sodium cholate (16% fat, 37% calories from fat, 1.25%
cholesterol, 0.125% choline chloride, 0.5% sodium cholate, TD90221, Harlan-Teklad,
Frederick, MD) for four weeks (28 days). Mouse livers were excised and homogenized (100
mg) in Qiazol Total RNA extraction buffer. All mice were housed, and the relevant studies
were completed, under active protocols approved by the National Institutes of Health,
National Heart, Lung and Blood Institute Animal Care and Use Committee. All protocols
complied with, and all animals received humane care according to, the criteria outlined in
the NIH "Guide for the Care and Use of Laboratory Animals".
High-throughput small RNA sequencing
miRNA isolation and Illumina sequencing were completed as previously reported(22).
Details are provided in Supplementary Methods.
Bioinformatics
Target sites (seed, centered) were predicted for miR-27b in both the 3’ UTRs and the open
reading frames of the 151 lipid metabolism genes. Details of target site prediction and the
identification of candidate miRNA regulatory hubs by Monte Carlo simulations are provided
in Supplementary Methods.
Cell Culture
Human hepatocytes (Huh7) were cultured in F12 DMEM, supplemented with 10% fetal
bovine serum, penicillin (100 U/mL), and streptomycin (100 µg/mL), and maintained at
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37°C with 5% CO2. For transfection, Huh7 cells were plated at 1 × 105 cells/mL for 24 h
prior to transient transfection (DharmaFECT4, Dharmacon, Lafayette, CO) with 10 nM
miR-27b miRIDIAN mimic (C-300589-05) or 10/100 nM HI-27b miRIDIAN hairpin
inhibitor (IH-300589-07) for 48 h.
Gene expression studies
Gene expression in Huh7 cells was assayed by microarray (Affymetrix GeneChIP Human
Genome U133A 2.0), real time PCR (Applied Biosystems TaqMan assays), and ELISA
according to standard protocols. Details of the methodology and reagents used are provided
in Supplementary Methods.
Reporter Gene (Luciferase) Assays
Reporter gene assays were conducted with a truncated 3’ UTR (bases 1-806) of human
GPAM (NM_020918.3), which was cloned downstream of firefly luciferase in a
pEZXMT01 vector (GeneCopoeia). Site-directed mutagenesis (QuickChange II XL,
Stratagene), using custom primers (Supplementary Table S4), was performed to alter the
predicted miR-27b target site at base 329 (G>A). Transformation, DNA extraction, transient
transfections, and Luciferase activity measurements were conducted according to standard
protocols, which are described in detail in the Supplementary Methods.
Lipid analysis
Murine plasma and hepatic lipid levels were measured according to standard enzymatic
quantification (Roche Diagnostics). Details of blood collection, tissue extraction, and
reagents used are provided in Supplementary Methods.
Statistics
When comparing two groups, Mann-Whitney non-parametric tests (two-tailed) were used
unless otherwise stated. For all tests, P-values ≤ 0.05 were considered significant. All results
are expressed as means +/− standard error, and n = derives from independent experiments.
RESULTS
High-throughput small RNA sequencing detects at least 150 miRNAs in mouse liver
To characterize mouse liver miRNAs, we performed high-throughput sequencing on a small
RNA library generated from mouse liver and obtained ~9.9 million small RNA reads
(Methods). Using an in-house bioinformatic strategy, we determined that ~40% (~3.9
million) of the reads matched exactly (no mismatches) to 160 annotated mouse miRNAs in
miRBase. Almost all of these miRNAs (n = 157) were represented by ≥ 3 exactlymatching
sequence reads and were thus identified as hepatic miRNAs (Figure 1A; Supplementary
Table S1). The diversity and number of hepatic miRNAs is consistent with results from the
few other previously published small RNA sequencing studies performed in other murine
tissues(23, 24). The most highly abundant miRNA, miR-122, accounts for ~90% of the
miRNA-related sequence reads in the mouse liver (Figure 1A). Nevertheless, many of the
less abundant miRNAs have been shown to regulate important processes in the liver, such as
miR-33 (cholesterol homeostasis, fatty acid oxidation)(20, 25), miR-22 (hepatocyte
proliferation)(26), miR-125a-5p (lipid uptake)(27), miR-30 (hepatobiliary development)
(28), and miR-29b (liver fibrosis)(29).
miR-27b is a regulatory hub in lipid metabolism
A post-transcriptional “miRNA hub” in lipid metabolism was defined as a miRNA that is
predicted to target more lipid metabolism-associated genes than expected by chance(30). To
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identify lipid metabolic miRNA hubs, we assembled a high-confidence list of 151 known
lipid metabolism associated genes (Supplementary Table S2) from three high-throughput
screens: [1] a large-scale hepatic gene expression analysis (microarray) of transgenic mice
over-expressing SREBF1 or SREBF2(31), [2] a systematic siRNA screen for lipid-
regulating genes assayed by quantitative analysis of cellular cholesterol levels(32), and [3] a
genome-wide screen for common genetic variants associated with plasma lipid levels(33).
Typically, the most effective miRNA target sites occur within 3’ untranslated regions (3’
UTRs) of mRNAs and have perfect base pairing with the “seed” region of the miRNA
(nucleotides 2 through 7 from the 5’-end of the miRNA)(34). For each of the 157 hepatic
miRNAs identified by small RNA sequencing, we scanned the 3’ UTRs of the 151 known
lipid metabolism-associated genes for seed-based target sites, and the number of genes with
at least one such predicted site was scored. We then performed Monte-Carlo simulations to
obtain the expected number of genes predicted to be targeted by chance for each miRNA.
Target sites for three hepatic miRNAs, namely miR-27b, miR-128, and miR-365, were
significantly over-represented (empirical uncorrected P < 0.01) in the 151 known lipid
metabolism genes. Among all mouse liver miRNAs, miR-27b had the most predicted lipid
metabolism gene targets (n=27) (empirical uncorrected P = 0.003) (Figure 1B). We repeated
this analysis for those miRNAs previously detected in human liver tissue by small RNA
cloning(35), and again miR-27 was the most significant (Figure 1C).
miR-27b levels are sensitive to plasma and hepatic lipid content
To identify lipid-responsive hepatic miRNAs, we used high-throughput small RNA
sequencing to quantify and compare miRNA expression in the livers of C57BL/6J mice on a
normal chow diet and on a high-fat “Western” diet (HFD, 42% calories from fat). After 3
weeks, triglyceride levels (mg/dL) were significantly increased in the plasma (1.86-fold, P =
0.0006) (Figure 2A) and liver (1.87-fold, P = 0.01) (Figure 2B) of HFD mice compared to
mice fed a normal chow diet. Analysis of the small RNA sequence data revealed that at least
50 miRNAs were ≥ 2-fold more abundant (percent of total reads) in HFD mouse liver
(Figure 2C, Supplementary Table S1), including miR-27b, which was up-regulated 3.2-fold
(Figure 2D). To confirm this observation, we performed real-time PCR using individual
TaqMan assays, and found miR-27b to be significantly increased (2.4-fold, P = 0.03) in
HFD livers compared to normal mouse livers (Figure 2E). However, interestingly, levels of
the primary transcript of miR-27b (pri-miR-27b) were not increased (Supplementary Figure
S1).
miR-27b represses critical regulators of lipid homeostasis
To validate miR-27b targeting of lipid metabolism genes experimentally, we transfected
miR-27b in human hepatocytes (Huh7 cells) and performed whole-genome microarray
expression analysis. Of the 13,785 unique genes assayed on the array, 1,318 were down-
regulated at FDR < 0.05, including ~10% of the original set of 151 known lipid metabolism
genes. Of these 1,318 genes, 173 were down-regulated by a fold-change < - 1.5 (Figure 3A;
Supplementary Table S3). We applied the Sylamer algorithm(36) to calculate enrichment
scores for all possible 6-mer motifs in the 3’ UTRs of the 13,785 genes, sorted according to
their level of down-regulation upon miR-27b over-expression. The most enriched 6-mer
motif among down-regulated genes is CTGTGA (Figure 3B), which is the exact reverse
complement of the miR-27b “canonical seed” region (nucleotides 2–7 from the 5’-end of the
miRNA) (34). The two next-most enriched motifs, TGTGAA and ACTGTG, are reverse
complements of the miR-27b seed region shifted by 1-nucleotide on either side (nucleotides
1–6 and 3–8 from the 5’-end of miR-27b, respectively). We next implemented an algorithm
that identifies “seed” target sites. Among the significantly down-regulated genes with
annotated 3’ UTR sequence (n=161), ~73% (n=118) have canonical miR-27b seed sites,
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which represents a 2.2-fold enrichment compared to background expectation (Fisher’s exact
test P < 0.0001) (Figure 3C). Non-canonical “shifted seed” sites are present in an additional
~9% (n=14) of the down-regulated genes, leaving ~18% (n=29) of the genes without any
predicted 3’ UTR target site.
To further validate miR-27b-mediated regulation of lipid metabolism genes, we introduced
miR-27b mimics or inhibitors (antagomiRs) into Huh7 cells by transient transfection. Over-
expression of miR-27b mimics resulted in a significant increase (552-fold, P = 0.02) in
intracellular miR-27b levels, and inhibition of endogenous miR-27b resulted in a significant
decrease (71% loss, P = 0.02) in intracellular miR-27b levels (Figure 4A). We then assayed
by real-time quantitative PCR the mRNA levels of six genes: Peroxisome proliferator-
activated receptor gamma (PPARG), Angiopoietin-like 3 (ANGPTL3), N-deacetylase/N-
sulfotransferase 1 (NDST1), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR),
Glycerol-3-phosphate acyltransferase 1, mitochondrial (GPAM), and Sterol regulatory
element binding factor 1 (SREBF1). These six genes were selected on the basis of their
well-established relevance to lipid metabolism (Supplementary Methods).
Four of the six genes were significantly down-regulated by miR-27b over-expression
(PPARG, P=0.0006; ANGPTL3, P<0.0001; NDST1, P=0.0008; and GPAM, P<0.0001;
Figure 4B–E) and one (HMGCR, P=0.06) was just outside of significance at the 5%
threshold (Figure 4F). Inhibition of endogenous miR-27b significantly up-regulated the
same four genes (PPARG, P=0.01; ANGPTL3, P<0.0001; NDST1, P=0.02; and GPAM,
P=0.004; Figure 4B–E). SREBF1 was not affected by miR-27b over-expression (Figure 4G).
To assess the influence of miR-27b targeting on protein levels of these key lipid metabolism
genes, secreted (ANGPTL3) and cellular (GPAM) protein levels were quantified by ELISA.
Inhibition of endogenous miR-27b by transient transfection of Huh7 cells with antagomiRs
significantly (P=0.002) increased secreted ANGPTL3 protein levels in the media after 48 hrs
(Figure 5A). miR-27b inhibition also resulted in significantly (P=0.04) increased cellular
GPAM levels (Figure 5B). To determine if miR-27b modulates PPARG transcriptional
activity, we performed PPARG binding assays with nuclear extracts from transfected Huh7
cells (Supplementary Methods). Inhibition of endogenous miR-27b resulted in a significant
(P=0.01) increase in PPARG binding to immobilized response elements (Supplementary
Figure S2). It should be noted that while over-expression of miR-27b significantly reduced
(39% loss, P=0.002) secreted ANGPTL3 levels (Figure 5A) after 48 hrs, cellular GPAM
protein levels and PPARG transcriptional activity were not affected (Figure 5B,
Supplementary Figure S2). These observations are likely explained at least in part by the
stability and temporal dynamics of each protein.
Next we searched for canonical 3’ UTR seed-based miR-27b target sites within each of the
six genes (Methods). As expected, SREBF1, which did not change (mRNA level) in
response to over-expression of either miR-27b mimic or its antagomiR, did not harbor any
canonical miR-27b seed sites (Figure 4F). Three out of the five genes that were repressed by
miR-27b (PPARG, NDST1, and GPAM) contained one or more seed sites within their 3’
UTRs (Figure 4A–E). GPAM harbors two highly conserved and one moderately conserved
miR-27b target site within its 3’ UTR (Figure 4). To determine if miR-27b directly targets
GPAM through one of these predicted sites, we performed reporter gene (luciferase) assays.
A portion of the GPAM 3’ UTR, containing one putative miR-27b site, was cloned
downstream of firefly luciferase (Methods). Dual transfection with miR-27b in HEK293
cells significantly (P=0.001) reduced firefly luciferase activity (Supplementary Figure S3).
After site-directed mutagenesis to eliminate the putative miR-27b site (Methods), miR-27b
failed to knock-down firefly luciferase activity, indicating that the site is directly involved in
miR-27b mediated regulation of GPAM (Supplementary Figure S3).
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ANGPTL3 was the only down-regulated gene that did not harbor any miR-27b seed sites in
its 3’ UTR. To further investigate the observed strong miR-27b-mediated regulation of
ANGPTL3 (Figure 4C, 5A), we expanded the search to two recently discovered classes of
target sites: [1] 3’ UTR centered sites and [2] open reading frame (ORF) sites (Methods). As
its name implies, 3’ UTR centered sites base pair to the center of the miRNA sequence(37),
as opposed to the 5'-end seed region. Functional ORF sites are typically preceded by a
stretch of rare codons(38), which can cause ribosomal pausing(39), thereby allowing
miRNA silencing complexes to form stable interactions with the target site without
ribosomal interference. We developed and implemented computational strategies to predict
3’ UTR centered sites based on the strength of base pairing to the center of a miRNA, and
ORF seed sites based on a metric that evaluates codon rarity in the preceding sequence
(Methods). Of the six genes examined, only ANGPTL3 was predicted to have both a 3’
UTR centered site and a high-confidence ORF target site for miR-27b (Figure 4C).
Furthermore, no other hepatic miRNA besides miR-27 was predicted to have high-
confidence ORF or 3’ UTR sites in ANGPTL3.
Hepatic miR-27b is up-regulated in a mouse model of dyslipidemia and atherosclerosis
We placed 8-week old Apoe−/− female mice on a high-fat/high-cholesterol diet (21% fat,
7.5% Cocoa butter), which has been shown to induce severe hypercholesterolemia and
advanced atherosclerosis(40, 41). To confirm the expected physiologic effects of this diet,
we measured plasma total cholesterol and triglyceride levels after four weeks. We observed
a significant increase in plasma cholesterol levels (4.6-fold, unpaired t-test P<0.001; Figure
6A) and a significant decrease in plasma triglycerides (~63% loss, unpaired t-test P=0.003;
Figure 6B) in the Apoe−/− mice fed the atherogenic diet.
After four weeks on the atherogenic diet, levels of both mature miR-27b (1.58-fold,
unpaired t-test P = 0.09) and pri-miR-27b (unpaired t-test P = 0.03) were increased in the
liver; Figure 6C–D). Based on this finding, we next assessed the hepatic expression of
miR-27b target genes. Consistent with the in vitro results, mRNA levels of both Angptl3
(~30% loss) and Gpam (~22% loss) were reduced (Supplementary Figure S4); however,
these observations were outside of statistical significance.
DISCUSSION
In this study we provide in silico, in vitro, and in vivo evidence that miR-27b is a strong
candidate regulatory hub in lipid metabolism. Based on Monte-Carlo simulations, miR-27b
was predicted to target significantly more lipid metabolism-associated genes than expected
by chance and more than any other hepatic miRNA. Two of the other miRNAs predicted to
be regulatory hubs in lipid metabolism (Figure 1B,C), miR-365 and miR-125, have
previously been shown to play roles in either adipocyte differentiation(42) or in cellular lipid
uptake(27), respectively, thus validating our approach.
High-throughput small RNA sequencing and real time quantitative PCR analysis revealed
that miR-27b is ~3.2-fold up-regulated in the livers of mice on a high-fat diet. miR-27b is
encoded with miR-23b and miR-24-1 in the same cistron on mouse chromosome 13. Small
RNA sequencing results suggest that both miR-23b and miR-24 are also up-regulated in the
liver of wild-type mice after high-fat diet, by ~2.2-fold and ~7.9-fold respectively. However,
we did not detect any change in the levels of their primary transcript, which suggests that:
(1) post-transcriptional mechanisms are completely responsible for the observed increase in
the mature miRNA levels, or (2) there is an increase in transcription of the miR-27b locus
but also a concomitant increase in the rate of processing of the primary transcript (i.e.
decreased pri-miR-27b stability). In contrast, Apoe−/− mice on an atherogenic diet were
found to have increased hepatic levels of both mature miR-27b and pri-miR-27b. While the
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latter finding is suggestive of enhanced transcription, several other recently reported post-
transcriptional mechanisms of miRNA expression control, including pri-miRNA tertiary
structure(43) and non-templated nucleotide additions(44), may also be involved and cannot
be ruled out.
Microarray and real time quantitative PCR based gene expression analyses in human
hepatocytes confirmed robust miR-27b-mediated regulation of key lipid metabolism genes,
including PPARG, GPAM, and ANGPTL3. Studies in rodents have revealed that both
GPAM and ANGPTL3 regulate lipid metabolism(45, 46). Recent genome-wide association
studies in human populations have added to these findings, by identifying genetic
polymorphisms in both GPAM and ANGPTL3 that are significantly associated with plasma
lipid levels(33).
GPAM is present in a variety of tissues; however, it is most highly expressed in the liver. It
is known to catalyze the first committed step in de novo triglyceride synthesis(47), and more
recently, has been implicated in regulating cholesterol(33). As such, over-expression of
GPAM in mouse liver results in fatty liver, hepatic steatosis, and plasma hyperlipidemia(48).
Our data show that hepatic Gpam mRNA levels are reduced in Apoe−/− mice on a four-week
atherogenic diet, concomitant with a decrease in plasma triglyceride levels and an increase
in hepatic miR-27b expression.
ANGPTL3 is expressed by the liver(49) and secreted into circulation(50), where it
suppresses the activity of lipoprotein lipase(51) and endothelial lipase(52), which regulate
triglyceride and HDL-cholesterol levels, respectively. Plasma levels of ANGPTL3 correlate
with various parameters of lipid/carbohydrate metabolism(53) and atherosclerosis(54), and
specific nonsense mutations in ANGPTL3 lead to hypolipidemia(55). While several tissues
may contribute to plasma ANGPTL3 levels, our data in this study reveal that hepatic
Angptl3 levels are decreased in Apoe−/− mice on a four-week atherogenic diet, concomitant
with an increase in hepatic miR-27b expression. It is possible that Gpam and Angptl3 are
repressed by miR-27b in the adaptive response to dyslipidemic conditions, in order to
mitigate the accumulation of lipids in circulation.
Further detailed in vivo experimentation is required to determine the extent to which
miR-27b targeting of GPAM and ANGPTL3 is required for controlling plasma lipid levels,
and whether modulation of endogenous miR-27b levels could serve as an effective
therapeutic strategy for lipid-related disorders.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. miR-27b is a strong candidate regulatory hub in lipid metabolism
(A) For each murine hepatic miRNA (x-axis), the read depth from small RNA-seq (y-axis;
logscale) is shown. (B) For each murine hepatic miRNA (x-axis), the negative logarithm of
the empirical p-value (y-axis) for the level of enrichment of predicted target sites in lipid-
related genes is shown. (C) For each known human hepatic miRNA (x-axis), the negative
logarithm of the empirical p-value (y-axis) for the level of enrichment of predicted target
sites in lipid-related genes is shown. Dashed lines indicate empirical P = 0.01 (green) and
empirical P = 0.05 (red).
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Figure 2. miR-27b is sensitive to hyperlipidemia
(A) Triglyceride levels (mg/dL) are significantly increased in the mouse plasma after three
weeks of HFD (chow n=7, high-fat diet (HFD) n=7). (B) Triglyceride levels (mg/dL) are
significantly increased in the mouse liver after three weeks of HFD (chow n=8, HFD n=8).
(C) Differential abundance of normalized mouse liver miRNA reads (Small RNA-seq) on
high fat diet is shown. Green lines represent 2-fold change. X-axis: Log2(percent total reads
chow diet), Y-axis: Log2(percent total reads HFD). Red circles indicate ≥ 2-fold change. (D)
Hepatic miR-27b expression levels, as determined by small RNA-seq, are significantly
increased in HFD (2995 reads / 3,825,273 total reads) relative to chow (955 reads /
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3,902,443 total reads). (E) Hepatic miR-27b expression levels, as determined by real-time
PCR, are significantly increased in HFD relative to chow. Relative quantitative value (RQV)
is represented as fold change to chow diet mean (chow, n=9; HFD, n=3). *, Mann-Whitney
non-parametric test P < 0.05.
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Figure 3. miR-27b over-expression in human hepatocytes significantly down-regulates 173 genes
(A) Results of a microarray analysis upon miR-27b over-expression (10 nM) in hepatocytes
are shown. 173 genes (green) are significantly down-regulated (Fold Change < −1.5, FDR <
0.05) and 128 genes (red) are significantly up-regulated (Fold Change > 1.5, FDR < 0.05).
(B) A sylamer plot of motif enrichment in the 3’ UTRs of the genes assayed on the
microarray is shown. The six-nucleotide motif matching the miR-27b “seed” region is the
most significantly enriched among down-regulated genes (left-most portion of graph). (C)
Canonical miR-27b seed-match sites are significantly overrepresented in the set of 161 most
down-regulated genes, whereas predicted seed-match sites for two control miRNAs,
miR-151a-5p and miR-122-5p, are not. **, Fisher’s exact test P < 0.0001.
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Figure 4. miR-27b represses key lipid metabolism genes
(A) Quantification by real-time PCR of intracellular mature miR-27b levels after transient
transfection (48 h) of miR-27b or HI-27b (anti-miR-27b) is shown. (B–G) Results of
microarray and real-time quantitative PCR (RT-qPCR) analysis upon miR-27b and HI-27b
over-expression (10 nM) in hepatocytes are shown. Microarray data: (B–D, F, G) Each
array group (+/−miR-27b), n=6. (E) No microarray data is shown for GPAM, because
probes for this gene were not present on the microarray. Real-time PCR data: (B) PPARG:
mock, n=7; miR-27b, n=7; and HI-27b, n=3. (C) ANGPTL3: mock, n=17; miR-27b, n=13;
and HI-27b, n=14. (D) NDST1: mock, n=13; miR-27b, n=9; and HI-27b, n=11. (E) GPAM:
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mock, n=16; miR-27b, n=19; and HI-27b, n=12. (F) HMGCR: mock, n=10; miR-27b, n=10;
and HI-27b, n=6. (F) SREBF1: mock, n=10; miR-27b, n=10. The mRNA levels of four
genes (PPARG, ANGPTL3, NDST1, and GPAM) are significantly reduced upon miR-27b
over-expression (black) and elevated upon HI-27b over-expression (shaded). PPARG,
NDST1, HMGCR, and GPAM each have at least one predicted “seed-based” 3’ UTR target
site for miR-27b. ANGPTL3 has both a predicted “centered” 3’ UTR site and a “seed-
based” coding-region site for miR-27b. P-value computations are based on the Mann-
Whitney non-parametric test. *, P < 0.05; **, P < 0.0001.
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Figure 5. Inhibition of miR-27b increases cellular GPAM and secreted ANGPTL3 protein levels
Results of ELISA from hepatocyte (Huh7) culture media or cellular extracts upon miR-27b
and HI-27b (anti-miR-27b) over-expression (10 nM) are shown. (A) ANGPTL3 protein
levels in hepatocyte culture media, normalized to total cellular protein (ng/mg), is shown
(n=6). (B) GPAM protein levels in cellular extracts, normalized to total cellular protein (ng/
mg), is shown (n=6). P-value computations are based on the Mann-Whitney non-parametric
test. *, P < 0.05.
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Figure 6. Hepatic miR-27b levels are increased in a mouse model of dyslipidemia and
atherosclerosis
(A) Plasma cholesterol levels are significantly increased in apolipoprotein E null (Apoe−/−)
mice on a Cocoa butter diet (CBD; black, n=4) compared to Apoe−/− mice on a chow diet
(white, n=4). (B) Triglyceride levels are decreased in Apoe−/− mice on a CBD (black, n=4)
compared to Apoe−/− mice on a chow diet (white, n=4). (C) Hepatic pri-miR-27b levels are
significantly increased in Apoe−/− mice on a CBD (black, n=4) compared to Apoe−/− mice
on a chow diet (white, n=4). (D) Hepatic mature miR-27b levels are increased in Apoe−/−
mice on a CBD (black, n=4) compared to Apoe−/− mice on a chow diet (white, n=4). P-value
computations are based on the unpaired t-test. *, P < 0.05.
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